Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 8/20 | 0.74 |
| ▸ | MAP1LC3B | Q9GZQ8 | 3/20 | 0.74 |
| ▸ | MEN1 | O00255 | 3/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.74 |
| ▸ | PLK4 | O00444 | 3/20 | 0.74 |
| ▸ | MAPT | P10636 | 3/20 | 0.74 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.74 |
| ▸ | PLK1 | P53350 | 2/20 | 0.74 |
| ▸ | EGFR | P00533 | 1/20 | 0.74 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.74 |
| ▸ | ARAF | P10398 | 1/20 | 0.74 |
| ▸ | PIM1 | P11309 | 1/20 | 0.74 |
| ▸ | BRAF | P15056 | 1/20 | 0.74 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.74 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.74 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.74 |
| ▸ | MYOC | Q99972 | 1/20 | 0.74 |
| ▸ | DYRK4 | Q9NR20 | 1/20 | 0.74 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.74 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1394878 | 1.00 | RAF1 (0.74) | RAF1MAP1LC3BMEN1KMT2APLK4 | |
| SCHEMBL1395212 | 0.90 | MAP1LC3B (0.69) | RAF1MAP1LC3BMEN1KMT2APLK4 | |
| SCHEMBL1395209 | 0.90 | MAP1LC3B (0.69) | RAF1MAP1LC3BMEN1KMT2APLK4 | |
| SCHEMBL1394784 | 0.89 | RAF1 (0.79) | RAF1MAP1LC3BMEN1KMT2APLK4 | |
| SCHEMBL4726411 | 0.89 | RAF1 (0.79) | RAF1MAP1LC3BMEN1KMT2APLK4 | |
| Gw305074X SCHEMBL29392050 | 0.86 | RAF1 (1.00) | RAF1MAP1LC3BMEN1KMT2APLK4 | |
| Gw305074X SCHEMBL149921 | 0.86 | RAF1 (1.00) | RAF1MAP1LC3BMEN1KMT2APLK4 | |
| Gw305074X SCHEMBL12199472 | 0.86 | RAF1 (1.00) | RAF1MAP1LC3BMEN1KMT2APLK4 | |
| Gw305074X SCHEMBL29389948 | 0.86 | RAF1 (1.00) | RAF1MAP1LC3BMEN1KMT2APLK4 | |
| Gw305074X SCHEMBL149922 | 0.86 | RAF1 (1.00) | RAF1MAP1LC3BMEN1KMT2APLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008021210-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | COMBINATORX, INCORPORATED (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | CHDI, INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| US-6268391-B1 | Benzylidene-1,3-dihydro-indol-2-one derivatives a receptor tyrosine kinase inhibitors, particularly of Raf kinases | GLAXO WELLCOME INC. | 2001-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | HTT, SNCA, NLN | RAF1 4132/4885MAP1LC3B 156/4885MEN1 3687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.